Patents by Inventor Wolfgang Stahle

Wolfgang Stahle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrido-Pyrimidine Derivatives
    Publication number: 20140228379
    Abstract: Compounds of the formula I in which Het, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of RON and can be employed, for the treatment of cancer
    Type: Application
    Filed: June 15, 2012
    Publication date: August 14, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang Stahle, Oliver Schadt, Christine Knuehl, Manja Friese-Hamim, Bayard Huck, Andreas Goutopoulos, Nadia Brugger
  • 1,3-BENZOXAZOLYL DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20120220611
    Abstract: Compounds of the formula I, the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases that are caused, mediated and/or propagated by angiogenesis. Compounds of the formula I are effective inhibitors of tyrosine kinases, in particular TIE-2 and VEGFR, and of Raf kinases.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 30, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang STÄHLE, Alfred JONCZYK, Wilfried RAUTENBERG
  • 1,3-benzoxazolyl derivatives as kinase inhibitors
    Patent number: 8242128
    Abstract: The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: August 14, 2012
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Stähle, Alfred Jonczyk, Wilfried Rautenberg
  • Benzylbenzimidazolyl derivatives
    Publication number: 20070066606
    Abstract: Novel benzyl-benzimidazolyl derivatives as inhibitors of tyrosine kinases, particularly TIE-2, VEGFR, PDGFR, FGFR and/or FLT/KDR, for the treatment of tumors, according to formula (I), wherein the radicals R1, R2, r and s are defined according to Claim (1).
    Type: Application
    Filed: August 17, 2004
    Publication date: March 22, 2007
    Inventors: Wolfgang Stahle, Alfred Jonczyk, Wilfried Rautenberg
  • Benzimidazolyl derivatives
    Publication number: 20070066660
    Abstract: The invention relates to the novel compounds of formula (I) wherein R1, R1, L, E, G, M, Q, U, R2, m, p and q are defined as in claim 1. The novel compounds are tyrosinkinase inhibitors, especially TIE-2 inhibitors, and Raf kinase inhibitors and can be used in the treatment of tumors.
    Type: Application
    Filed: October 14, 2004
    Publication date: March 22, 2007
    Applicant: Merck Patent GmbH
    Inventors: Wolfgang Stahle, Hans-Peter Buchstaller, Alfred Jonczyk, Wilfried Rautenberg
  • Kappa agonists, especialy for the treatment and/or prophylaxis of irritable bowel syndrome
    Publication number: 20060178426
    Abstract: Compound of the formula (I), in which A, R1, R2, R3, X, Y, m and n have the meaning indicated, are suitable as for the treatment of irritable bowel syndrome.
    Type: Application
    Filed: June 18, 2004
    Publication date: August 10, 2006
    Inventors: Wolfgang Stahle, Rudolf Gottschlich, Jurgen Harting, Christoph Seyfried
  • Inhibitors of integrin alphavbeta6
    Publication number: 20040092454
    Abstract: Novel biphenyl derivatives of the general formula (I) in which R1, R1′, R1″, R2, R2′, R3 and n are as defined in claim 1, their stereoisomers and their physiologically acceptable salts or solvates are novel integrin inhibitors which preferentially inhibit the &agr;v&bgr;6 integrin receptor. The novel compounds can be used, in particular, as medicaments.
    Type: Application
    Filed: September 15, 2003
    Publication date: May 13, 2004
    Inventors: Oliver Schadt, Alfred Jonczyk, Wolfgang Stahle, Simon Goodman
  • Urea and urethane derivatives as integrin inhibitors
    Publication number: 20040063644
    Abstract: Novel urea and urethane derivatives of general formula (I) in which R1, R2, R3, R5, R5′, X, Y, B, m, n and o are as defined in Patent claim 1, and physiologically acceptable salts or solvates thereof are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart disease, arteriosclerosis, inflammation, tumours. Osteoporosis, infections and restenosis after angioplasty or in pathological processes maintained or propagated by antiogenesis.
    Type: Application
    Filed: June 18, 2003
    Publication date: April 1, 2004
    Inventors: Wolfgang Stahle, Alfred Joncyk, Oliver Schadt, Simon Goodman
  • Biphenyl derivatives and the use thereof as integrin inhibitors
    Publication number: 20040010023
    Abstract: The invention relates to novel biphenyl derivatives of the general formula (I), wherein R4 represents an aromatic heterocycle, and to the physiologically acceptable salts or solvates thereof. The inventive compounds are integrin inhibitors and are used for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammations, tumors, osteoporosis, infections and restenosis following angioplasty or for pathological processes that are maintained or propagated by angiogenesis.
    Type: Application
    Filed: February 21, 2003
    Publication date: January 15, 2004
    Inventors: Wolfgang Stahle, Gunter Holzemann, Simon Goodman
  • Biphenyl derivatives and the use thereof as integrin inhibitors
    Publication number: 20030187289
    Abstract: Novel biphenyl derivatives of the general formula (I), in which Y, R R1, R2, R3, R4, m, o and p are as defined in claim 1, and their physiologically acceptable salts and solvates are integrin inhibitors and can be employed for combating thrombosis, cardiac infarction, coronary heart disease, arteriosclerosis, inflammation, tumours, osteoporosis, infections aid restenosis after angioplasty or in pathological processes which are maintained or propagated by angiogenesis.
    Type: Application
    Filed: February 21, 2003
    Publication date: October 2, 2003
    Inventors: Wolfgang Stahle, Simon Goodman
  • &bgr;-alanine derivatives
    Patent number: 6576637
    Abstract: The invention relates to &bgr;-alanine derivatives of formula (I), wherein Q1, Q2, Q3, Q4, R1, R2, R3, R4, R5, R6 and n have the meaning as disclosed in the disclosure, and to their physiologically acceptable salts or solvates. Said substances are integrin inhibitors and can be used in the treatment of thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, tumors, osteoporosis, infections and restenosis after angioplasty or in pathological processes induced or propagated by angiogenesis.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: June 10, 2003
    Assignee: Merck Patent GmbH
    Inventors: Günter Hölzemann, Simon Goodmann, Alfred Jonczyk, Wolfgang Stähle
  • Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis
    Patent number: 6521646
    Abstract: Compounds of the formula (I) and their physiologically acceptable salts and solvates are useful as integrin-inhibiting substances. They are especially useful in the prophylaxis and treatment of cardiovascular disorders, of thrombosis, cardiac infarction, coronary heart diseases, arteriosclerosis, osteoporosis, in pathological conditions that are caused or propagated by angiogenesis and in tumor therapy.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: February 18, 2003
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Stähle, Rudolf Gottschlich, Simon Goodman